A repeat scan 3 months after starting BRAF/MEK therapy demonstrated regression of her metastatic disease in the liver, spleen, and peritoneum, and decompression of her inferior vena cava with marked clinical and radiographic improvement (Figure 1). The gene discussed is MAP2K7; the disease is metastatic neoplasm.